During disease progression, CRC cells may develop resistance to TGF‐β by acquiring mutations in key players of the canonical TGF‐β signaling pathway, such as TGF‐β receptors or SMAD proteins [3]. The gene discussed is TGFB1; the disease is colorectal carcinoma.